[go: up one dir, main page]

AR111419A1 - Compuestos fusionados de indazol piridona como antivirales - Google Patents

Compuestos fusionados de indazol piridona como antivirales

Info

Publication number
AR111419A1
AR111419A1 ARP180101043A ARP180101043A AR111419A1 AR 111419 A1 AR111419 A1 AR 111419A1 AR P180101043 A ARP180101043 A AR P180101043A AR P180101043 A ARP180101043 A AR P180101043A AR 111419 A1 AR111419 A1 AR 111419A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
optionally substituted
ring
cycloalkyl
Prior art date
Application number
ARP180101043A
Other languages
English (en)
Inventor
Joseph Michael Young
Keith Brice Pfister
Peichao Lu
Subramanian Karur
Wooseok Han
Jiping Fu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR111419A1 publication Critical patent/AR111419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: R¹ es H o halo; R² se selecciona independientemente en cada aparición entre halo, CN, haloalquilo C₁₋₃, haloalcoxi C₁₋₃, -OR³, -N(R)R³, y alquilo C₁₋₃ opcionalmente sustituido con hasta tres grupos seleccionados entre R³, -N(R)R³, CN, -OH, -CONR₂, -COOR, y -OR³; R³ es un alquilo C₁₋₄ que está opcionalmente sustituido con uno a tres grupos seleccionados de halo, haloalquilo C₁₋₃, -OH, alcoxi C₁₋₃, haloalcoxi C₁₋₃, oxo, CN, -NH₂, -NH(alquilo C₁₋₃), -N(alquilo C₁₋₃)₂, -COOR, -CONR₂, cicloalquilo C₃₋₅, y un éter cíclico de 4 - 6 miembros, en el que el cicloalquilo C₃₋₅ y el éter cíclico de 4 - 6 miembros están cada uno opcionalmente sustituidos con uno o dos grupos seleccionados de halo, -OH, alcoxi C₁₋₃, y alquilo C₁₋₃; o R³ es un anillo cicloalquilo C₃₋₅ o éter cíclico de 4 - 6 miembros, en el que el anillo cicloalquilo C₃₋₅ o éter cíclico de 4 - 6 miembros están cada uno opcionalmente sustituidos con uno a tres grupos seleccionados de halo, alquilo C₁₋₃, -OH, alcoxi C₁₋₃, haloalcoxi C₁₋₃, haloalquilo C₁₋₃, -NH₂, -NH(alquilo C₁₋₃), y -N(alquilo C₁₋₃)₂; n es 0, 1, ó 2; W es -COOR⁴, -C(O)NH-SO₂R⁵, -C(O)NH-SO₂NR₂, 5-tetrazolilo, o 1,2,4-oxadiazol-3-il-5(4H)-ona; R⁴ es H o alquilo C₁₋₆ que está opcionalmente sustituido con uno a tres grupos seleccionados de halo, -OR, oxo, CN, y -NR₂; R⁵ es alquilo C₁₋₆ que está opcionalmente sustituido con uno a tres grupos seleccionados de halo, -OR, oxo, CN, y-NR₂; R⁶ es H o alquilo C₁₋₆; R⁷ es H o alquilo C₁₋₆, o R⁷ tomado junto con R⁹ y los átomos que los unen R⁷ con R⁹ forman un anillo como se describe a continuación; R⁸ es H o alquilo C₁₋₆; R⁹ se selecciona entre: (i) H; (ii) alquilo C₁₋₆ opcionalmente sustituido con hasta tres grupos seleccionados entre cicloalquilo C₃₋₆, -OR, -NR₂, halo, CN, COOR, CONR₂, y oxo; y (iii) un anillo seleccionado de (a) cicloalquilo C₃₋₆, (b) fenilo, (c) heterociclilo de 5 - 6 miembros que contiene uno o dos heteroátomos seleccionados de N, O y S como miembros del anillo, y (d) heteroarilo de 5 - 6 miembros que contiene uno o dos heteroátomos seleccionados de N, o y S como miembros del anillo, en el que cada uno de los anillos (a) a (d) está opcionalmente sustituido con hasta tres grupos seleccionados de alquilo C₁₋₂, (CH₂)₀₋₂-OR, -NR₂, halo, CN, COOR, y CONR₂; o R⁹ tomado junto con R⁷ y los átomos que los unen R⁹ con R⁷ forma un anillo cicloalquilo de 3 - 7 miembros, o un anillo heterocíclico de 3 - 7 miembros que contiene N, O ó S como miembro de anillo; en donde el anillo cicloalquilo o heterocíclico está opcionalmente sustituido con hasta tres grupos seleccionados de entre R, -OR, -NR₂, halo, CN, COOR, CONR₂, y oxo; R se selecciona independientemente en cada caso de H y alquilo C₁₋₃ opcionalmente sustituido con uno a tres grupos seleccionados de halo, -OH, alcoxi C₁₋₃, oxo, CN, -NH₂, -NH(alquilo C₁₋₃), -N(alquilo C₁₋₃)₂, y ciclopropilo; y dos grupos R unidos directamente al mismo átomo pueden tomarse opcionalmente junto con el átomo al que ambos están unidos para formar un anillo de 3 - 6 miembros que puede contener opcionalmente un heteroátomo seleccionado de N, O y S como miembro del anillo, y puede estar sustituido con hasta dos grupos seleccionados de -OH, oxo, alquilo C₁₋₃ y alcoxi C₁₋₃; o una sal farmacéuticamente aceptable del mismo.
ARP180101043A 2017-04-27 2018-04-24 Compuestos fusionados de indazol piridona como antivirales AR111419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762490890P 2017-04-27 2017-04-27

Publications (1)

Publication Number Publication Date
AR111419A1 true AR111419A1 (es) 2019-07-10

Family

ID=62148437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101043A AR111419A1 (es) 2017-04-27 2018-04-24 Compuestos fusionados de indazol piridona como antivirales

Country Status (9)

Country Link
US (3) US10301312B2 (es)
EP (2) EP3615533B1 (es)
JP (1) JP7290573B2 (es)
CN (1) CN110831942B (es)
AR (1) AR111419A1 (es)
ES (1) ES2899922T3 (es)
TW (1) TWI810182B (es)
UY (1) UY37699A (es)
WO (1) WO2018198079A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
CN109069488B (zh) 2016-03-07 2021-09-07 英安塔制药有限公司 乙型肝炎抗病毒剂
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
CN111433210A (zh) * 2017-12-20 2020-07-17 诺华股份有限公司 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020043080A1 (en) 2018-08-28 2020-03-05 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
KR20210069680A (ko) 2018-09-30 2021-06-11 선샤인 레이크 파르마 컴퍼니 리미티드 융합된 사환형 화합물 및 약물에서의 이의 용도
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021018207A1 (zh) * 2019-07-30 2021-02-04 上海挚盟医药科技有限公司 一类用于治疗和/或预防乙型肝炎病毒感染的化合物及其制备方法和应用
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN120051281A (zh) * 2022-10-04 2025-05-27 蓝樫鸟医药公司 吲唑吡啶酮化合物及其用途
WO2024263770A1 (en) * 2023-06-21 2024-12-26 The Trustees Of The University Of Pennsylvania Toll-like receptor (tlr) agonist lipidoid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
AU2003218989A1 (en) 2002-02-19 2003-09-09 Pharmacia Italia S.P.A. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2012518598A (ja) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3099685B1 (en) 2014-01-30 2018-04-18 F.Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
SI3114128T1 (sl) 2014-03-07 2019-04-30 F. Hoffmann-La Roche Ag Novi 6-spojeni heteroarildihidropirimidini za zdravljenje in preprečevanje okužbe z virusom hepatitisa B
KR20160148715A (ko) * 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2017016921A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
EP3328855B1 (en) 2015-07-27 2019-05-15 H. Hoffnabb-La Roche Ag Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017102648A1 (en) 2015-12-15 2017-06-22 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
WO2017108630A1 (en) 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017114812A1 (en) 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an interferon
UY37128A (es) 2016-02-19 2017-09-29 Novartis Ag Compuestos tetracíclicos de piridona como antivirales
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
TW201819380A (zh) * 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
CN106928215B (zh) 2017-03-06 2019-03-22 河南春风医药科技有限公司 一种喹嗪酮类化合物的制备方法
CN106928245B (zh) 2017-03-06 2019-06-11 河南春风医药科技有限公司 一种喹嗪酮类化合物及其制备方法和应用
AR111419A1 (es) * 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales

Also Published As

Publication number Publication date
JP2020517667A (ja) 2020-06-18
EP3615533B1 (en) 2021-09-08
TWI810182B (zh) 2023-08-01
TW201841919A (zh) 2018-12-01
EP3998269A1 (en) 2022-05-18
UY37699A (es) 2018-11-30
US20180312507A1 (en) 2018-11-01
US10975078B2 (en) 2021-04-13
US20200270252A1 (en) 2020-08-27
WO2018198079A1 (en) 2018-11-01
US10301312B2 (en) 2019-05-28
US20190300530A1 (en) 2019-10-03
JP7290573B2 (ja) 2023-06-13
ES2899922T3 (es) 2022-03-15
CN110831942B (zh) 2023-04-04
CN110831942A (zh) 2020-02-21
EP3615533A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
AR111419A1 (es) Compuestos fusionados de indazol piridona como antivirales
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR106799A1 (es) Inhibidores éster de acc y usos de los mismos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR106806A1 (es) Inhibidores triazol de acc y usos de los mismos
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR096332A1 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR099111A1 (es) Derivados de azepano y su uso para tratar infecciones de hepatitis b
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR110298A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure